Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)
Cathomas R, Gillessen Sommer S, Manetsch G, Bernhard J, Mohaupt M, Roggero E, Rauch D, Vilei S, Hayoz S, Kenner H, von Burg P, Elliott T, Rothermundt C, Winterhalder R, Mark M, Crabb S, Swiss Group for Clinical Cancer Research SAKK. Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). Prostate 2016; 76:1519-1527.
25.07.2016
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)
25.07.2016
Prostate 2016; 76:1519-1527
Cathomas Richard, Gillessen Sommer Silke, Manetsch Gabriela, Bernhard Jürg, Mohaupt Markus G, Roggero Enrico, Rauch Daniel, Vilei Simona Berardi, Hayoz Stefanie, Kenner Heike, von Burg Philippe, Elliott Tony, Rothermundt Christian, Winterhalder Ralph, Mark Michael, Crabb Simon J, Swiss Group for Clinical Cancer Research SAKK
Weiter
